BACKGROUND: Previous comparisons of peritonitis rates between continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD) have produced varying results. METHODS: Using United States Renal Data System data, the authors evaluated peritonitis rates in 1994 through 1997 incident CAPD (n = 9,190) and CCPD (n = 2,785) Medicare patients. Patients were characterized during a 6-month entry period (months 4 through 9) and followed for a maximum of 2 years (months 10 through 33). Medicare claims data provided the date of the first peritonitis episode during the follow-up period. The time to first peritonitis after 9 months of PD was compared by the log-rank test, and then by Cox regression with adjustment for peritoneal dialysis modality, age, sex, race, primary end-stage renal disease (ESRD) diagnosis, number of entry-period hospital days, peritonitis during the entry period, hematocrit value, and congestive heart failure. RESULTS: For CAPD and CCPD, the adjusted average months to first peritonitis after 9 months of PD were 17.1 and 16.1, respectively. The probabilities of remaining without a peritonitis episode after 1 year of follow-up were 0.53 and 0.50, respectively ( P = 0.008). The risk of peritonitis was lower for CAPD than for CCPD (relative risk, 0.939; 95% confidence interval, 0.883 to 0.998). Other significant risk factors included age <or=44 years, black race, diabetes as primary ESRD diagnosis, peritonitis during the entry period, greater than 4 entry-period hospital days, and congestive heart failure. Patients treated with recombinant human erythropoietin with a hematocrit value of >or=36% had lower risk of peritonitis. CONCLUSION: Compared with CCPD, CAPD is associated with a slightly but significantly lower risk for development of a first peritonitis episode after 9 months of peritoneal dialysis therapy.
BACKGROUND: Previous comparisons of peritonitis rates between continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD) have produced varying results. METHODS: Using United States Renal Data System data, the authors evaluated peritonitis rates in 1994 through 1997 incident CAPD (n = 9,190) and CCPD (n = 2,785) Medicare patients. Patients were characterized during a 6-month entry period (months 4 through 9) and followed for a maximum of 2 years (months 10 through 33). Medicare claims data provided the date of the first peritonitis episode during the follow-up period. The time to first peritonitis after 9 months of PD was compared by the log-rank test, and then by Cox regression with adjustment for peritoneal dialysis modality, age, sex, race, primary end-stage renal disease (ESRD) diagnosis, number of entry-period hospital days, peritonitis during the entry period, hematocrit value, and congestive heart failure. RESULTS: For CAPD and CCPD, the adjusted average months to first peritonitis after 9 months of PD were 17.1 and 16.1, respectively. The probabilities of remaining without a peritonitis episode after 1 year of follow-up were 0.53 and 0.50, respectively ( P = 0.008). The risk of peritonitis was lower for CAPD than for CCPD (relative risk, 0.939; 95% confidence interval, 0.883 to 0.998). Other significant risk factors included age <or=44 years, black race, diabetes as primary ESRD diagnosis, peritonitis during the entry period, greater than 4 entry-period hospital days, and congestive heart failure. Patients treated with recombinant humanerythropoietin with a hematocrit value of >or=36% had lower risk of peritonitis. CONCLUSION: Compared with CCPD, CAPD is associated with a slightly but significantly lower risk for development of a first peritonitis episode after 9 months of peritoneal dialysis therapy.
Authors: Luiz Gustavo Oliveira; Juliana Luengo; Jacqueline C T Caramori; Augusto C Montelli; Maria de Lourdes R S Cunha; Pasqual Barretti Journal: Int Urol Nephrol Date: 2012-10 Impact factor: 2.370
Authors: Luis C Martin; Jacqueline C T Caramori; Natalia Fernandes; Jose C Divino-Filho; Roberto Pecoits-Filho; Pasqual Barretti Journal: Clin J Am Soc Nephrol Date: 2011-07-07 Impact factor: 8.237
Authors: Rajnish Mehrotra; Melissa Soohoo; Matthew B Rivara; Jonathan Himmelfarb; Alfred K Cheung; Onyebuchi A Arah; Allen R Nissenson; Vanessa Ravel; Elani Streja; Sooraj Kuttykrishnan; Ronit Katz; Miklos Z Molnar; Kamyar Kalantar-Zadeh Journal: J Am Soc Nephrol Date: 2015-12-10 Impact factor: 10.121
Authors: Annie-Claire Nadeau-Fredette; David W Johnson; Carmel M Hawley; Elaine M Pascoe; Yeoungjee Cho; Philip A Clayton; Monique Borlace; Sunil V Badve; Kamal Sud; Neil Boudville; Stephen P McDonald Journal: Perit Dial Int Date: 2016-01-13 Impact factor: 1.756
Authors: Jenny I Shen; Aya A Mitani; Anjali B Saxena; Benjamin A Goldstein; Wolfgang C Winkelmayer Journal: Perit Dial Int Date: 2012-10-02 Impact factor: 1.756
Authors: Raja Zabaneh; Simon D Roger; Mohamed El-Shahawy; Michael Roppolo; Grant Runyan; Janet O'Neil; Ping Qiu Journal: Perit Dial Int Date: 2014-03-01 Impact factor: 1.756